Cohance Lifesciences Announces Special Window for Re-lodgement of Physical Share Transfer Requests
Cohance Lifesciences opens a special window from July 7, 2025, to January 6, 2026, for re-lodging physical share transfer requests rejected before April 1, 2019. Shareholders should contact KFin Technologies Limited for assistance. Advertisements were published on December 27, 2025.
This is a routine regulatory compliance announcement related to a specific type of share transfer process and is unlikely to have a material impact on the company's stock price or business operations.
The announcement is a procedural update regarding share transfers and does not contain significant financial or business performance information that would warrant a positive or negative sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced a special window for the re-lodgement of transfer requests for physical shares. This facility is available from July 07, 2025, to January 06, 2026. It is intended for shareholders who had lodged transfer requests for physical shares prior to the April 01, 2019 deadline, but which were rejected, returned, or not attended to due to deficiencies in documentation or process.
Shareholders wishing to utilize this opportunity are advised to contact the Company's Registrar and Share Transfer Agent, KFin Technologies Limited, at einward.ris@kfintech.com or call 1800-309-4001. The unit handling this is Cohance Lifesciences Limited, located at Selenium Tower B, Plot 31-32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad-500 032.
This notice is issued in compliance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025. The announcement also mentions that the company has published newspaper advertisements regarding this special window in Business Standard (English Daily) and Navshakti (Marathi Daily) on December 27, 2025. This information will also be available on the company's website at https://www.cohance.com/corporate-info/.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under share transfer updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.